摘要
利什曼病和查加斯病是热带国家的地方病。这些问题造成高发病率和公共卫生问题。目前的化疗是以传统药物为基础的,其疗效和毒性与治疗方案的长短和高剂量有关。当两种药物结合成一个分子时,结果就是所谓的杂化分子.在寻找防治查加斯病和利什曼病的新方法方面,已有研究表明,杂合分子具有较高的抗原虫活性,在新药发现和开发领域具有广阔的应用前景。本文综述了从药效团杂交中获得的不同杂交种的抗原生动物活性,表明其主要作用集中在喹啉、查尔酮和腙分子的分子杂交上。
关键词: 药物化学,抗原虫,杂交,利什曼病,有机化学,锥虫病。
Current Medicinal Chemistry
Title:Hybrid Molecules: Promising Compounds for the Development of New Treatments Against Leishmaniasis and Chagas Disease
Volume: 25 Issue: 30
关键词: 药物化学,抗原虫,杂交,利什曼病,有机化学,锥虫病。
摘要: Leishmaniasis and Chagas disease are endemic pathologies in tropical countries. These cause high morbidity and a public health problem. Current chemotherapies are based on conventional drugs with variable efficacy and toxicity related with the length of therapeutic schemes and high doses. When two pharmacological agents are combined into a single molecule, the result is the so-called hybrid molecule. In the search for new treatments against Chagas disease and leishmaniasis, several studies have shown that hybrid molecules display high antiprotozoal activity and this emerging strategy is quite promising in the field of new drug discovery and development. This review focuses on the antiprotozoal activity of different hybrids obtained from the hybridization of pharmacophores, showing that the most of the efforts have been concentrated in the molecular hybridization of quinoline, chalcone and hydrazone moieties.
Export Options
About this article
Cite this article as:
Hybrid Molecules: Promising Compounds for the Development of New Treatments Against Leishmaniasis and Chagas Disease, Current Medicinal Chemistry 2018; 25 (30) . https://dx.doi.org/10.2174/0929867325666180309111428
DOI https://dx.doi.org/10.2174/0929867325666180309111428 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements